Epstein Secrets

CTORIA R KAUFMANN,MAXIMILLIAN LAVAN,SPENCER WOOLEMS,HEATHER ZEITZ,GLENN

CE STUART TURNER,MARY FRANCES WEISS,HOWARD A CLONINGER,JEFFREY A LA MAISONETTE C

by other forms of muscular dystrophy. "Muscle studies have been underfunded forever and certainly a rare disease like 2a especially underfunded," Spencer says. In 2010, Wrubel formed the nonprofit Coalition to Cure Calpain 3. In the quest for a cure, she says, "It's a matter of patients taking charg

ion to dirty modes of transport, and taking us on a detour from a low-carbon path. At the Primus headquarters, I first meet Primus's chief chemist Howard Fang in front of a prototype of a Primus conversion machine. Fang, who joined the company for what he calls his "semi-retirement," is ILLUSTRATION BY P

ction to dirty modes of transport, and taking us on a detour from a low-carbon path. At the Primus headquarters, I first meet Primus’s chief chemist Howard Fang in front of a prototype of a Primus conversion machine. Fang, who joined the company for what he calls his “semi-retirement,” is ILLUSTRATION BY PET

t from orphan drugs because, compared to drugs for common afflictions, they often have shorter and less expensive clinical trials, with more success. Spencer says a drug for calpamnopathy, for instance, would also be useful for patients with Lou Gehrig’s Disease and bed rest patients, as it would help arre

wed by other forms of muscular dystrophy. “Muscle studies have been underfunded forever and certainly a rare disease like 2a especially underfunded,” Spencer says. In 2010, Wrubel formed the nonprofit Coalition to Cure Calpain 3. In the quest for a cure, she says, “It’s a matter of patients taking charge